Chemotherapy in advanced androgen-independent prostate cancer 1990–1999: A decade of progress?
Open Access
- 1 December 2000
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 11 (12) , 1523-1530
- https://doi.org/10.1023/a:1008394823889
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamideProstate Cancer and Prostatic Diseases, 1999
- PHASE II STUDY OF ALL-TRANS RETINOIC ACID ADMINISTERED INTERMITTENTLY FOR HORMONE REFRACTORY PROSTATE CANCERJournal of Urology, 1999
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerNew England Journal of Medicine, 1998
- Pyrazoloacridine for the Treatment of Hormone-Refractory Prostate CancerCancer Investigation, 1998
- Oral estramustine and oral etoposide for hormone-refractory prostate cancerUrology, 1997
- Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostateUrologic Oncology: Seminars and Original Investigations, 1995
- Hormone-refractory (D3) prostate cancer: Refining the conceptUrology, 1995
- P-glycoprotein Binding and Modulation of the Multidrug-Resistant Phenotype by EstramustineJNCI Journal of the National Cancer Institute, 1994
- Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.The Journal of cell biology, 1988
- The flare phenomenon on radionuclide bone scan in metastatic prostate cancerAmerican Journal of Roentgenology, 1984